AXDX Stock Overview
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.
Accelerate Diagnostics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.65|
|52 Week High||US$7.19|
|52 Week Low||US$0.50|
|1 Month Change||5.10%|
|3 Month Change||41.03%|
|1 Year Change||-70.85%|
|3 Year Change||-90.90%|
|5 Year Change||-91.67%|
|Change since IPO||931.25%|
Recent News & Updates
Accelerate Diagnostics spikes as Chief Technology Officer raises stake
The shares of in vitro diagnostics firm Accelerate Diagnostics, Inc. (NASDAQ:AXDX) jumped Tuesday after its Chief Technology Officer Larry Michael Mertz announced the purchase of 50K company shares. According to a regulatory filing today, Mr. Mertz bought $80K worth of AXDX shares at $1.60 apiece on Aug. 30, raising his stake by ~13%. The latest transaction comes a week after Mr. Mertz added ~51.7K AXDX shares, increasing his ownership in the company by ~16%. Mertz has served as the Senior Vice President, Head of R&D at AXDX since May 2021. The insider trading comes after the company recently announced a public offering of 17.5M shares of common stock at $2.00 per share. The share issuance was expected to raise $35M in gross proceeds for general corporate purposes and commercialization efforts.
Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders will have a reason to smile today, with the analysts making...
|AXDX||US Medical Equipment||US Market|
Return vs Industry: AXDX underperformed the US Medical Equipment industry which returned -25.9% over the past year.
Return vs Market: AXDX underperformed the US Market which returned -18.8% over the past year.
|AXDX Average Weekly Movement||24.1%|
|Medical Equipment Industry Average Movement||8.6%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: AXDX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 24% a week.
Volatility Over Time: AXDX's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Accelerate Diagnostics, Inc. Fundamentals Summary
|AXDX fundamental statistics|
Is AXDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AXDX income statement (TTM)|
|Cost of Revenue||US$13.74m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.64|
|Net Profit Margin||-480.03%|
How did AXDX perform over the long term?See historical performance and comparison